This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Recently, the phase II HUDSON trial demonstrated the feasibility of testing multiple immunotherapy-based combinations simultaneously, with biomarker-driven treatment matching where possible, in patients with non-small cell lung cancer. The study provides an example of how novel trial designs can improve the efficiency of drug testing.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on March 9, 2021
doi: 10.1158/2159-8290.CD-NB2021-0322
Multidrug Combo Testing Feasible in NSCLC
Jump to section
Advertisement